Correction: combination treatment with rucaparib (Rubraca) and MDM2 inhibitors, nutlin-3 and RG7388, has synergistic and dose reduction potential in ovarian cancer

Zanjirband, M.; Curtin, N.; Edmondson, Richard J; Lunec, J.

dc.contributor.author	Zanjirband, M.	en
dc.contributor.author	Curtin, N.	en
dc.contributor.author	Edmondson, Richard J	en
dc.contributor.author	Lunec, J.	en
dc.date.accessioned	2024-06-27T07:21:13Z
dc.date.available	2024-06-27T07:21:13Z
dc.date.issued	2024	en
dc.identifier.citation	Zanjirband M, Curtin N, Edmondson RJ, Lunec J. Correction: Combination treatment with rucaparib (Rubraca) and MDM2 inhibitors, Nutlin-3 and RG7388, has synergistic and dose reduction potential in ovarian cancer. Oncotarget. 2024 Feb 22;15:142. PubMed PMID: 38386812. Pubmed Central PMCID: PMC10883681. Epub 2024/02/22. eng.	en
dc.identifier.pmid	38386812	en
dc.identifier.doi	10.18632/oncotarget.28523	en
dc.identifier.uri	http://hdl.handle.net/10541/626989
dc.language.iso	en	en
dc.relation.url	https://dx.doi.org/10.18632/oncotarget.28523	en
dc.title	Correction: combination treatment with rucaparib (Rubraca) and MDM2 inhibitors, nutlin-3 and RG7388, has synergistic and dose reduction potential in ovarian cancer	en
dc.type	Other	en
dc.contributor.department	Faculty Institute for Cancer Sciences, University of Manchester, Manchester M13 9WL, United Kingdom.	en
dc.identifier.journal	Oncotarget	en
dc.description.note		en]
refterms.dateFOA	2024-07-01T14:53:15Z